中國同輻(01763.HK)獲批華北同位素藥品研發生產基地項目建設用地
格隆匯 10 月 27日丨中國同輻(01763.HK)發佈公告,2020年10月23日,中國同輻所屬原子高科華北醫藥有限公司在河北省涿州市公共資源交易中心順利獲得華北同位素藥品研發生產基地項目建設用地(涿州市2020-36號國有建設用地),標誌着該項目進入了實質實施階段。
華北醫藥基地項目由原子高科的全資附屬公司原子高科華北醫藥有限公司籌建。根據公司發展戰略,原子高科將在河北省涿州市松林店經濟開發區建設華北醫藥基地項目。項目主要建設內容包括現代核醫學臨牀廣泛應用的放射性藥品生產車間及其配套設施、研發設施等,項目建成後將成為亞洲最大的同位素藥品研發生產基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.